COSMO PHARMACEUTICALS NV (C43.DE) Forecast, Price Target & Analyst Ratings
FRA:C43 • NL0011832936
48.8 EUR
-1.2 (-2.4%)
Last: Apr 29, 2025, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for COSMO PHARMACEUTICALS NV (C43.DE).
Forecast Snapshot
Consensus Price Target
€104.72
+ 114.58% Upside
Next Earnings Forecast
Release DateJul 23, 2025
ChartMill Buy Consensus
84.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
€104.72
Upside
+ 114.58%
From current price of €48.80 to mean target of €104.72, Based on 10 analyst forecasts
Low
€83.80
Median
€95.88
High
€146.67
Price Target Revisions
1 Month
0.00%
3 Months
1.53%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for C43.DE. The average price target is 104.72 EUR. This implies a price increase of 114.58% is expected in the next year compared to the current price of 48.8.
The average price target has been revised upward by 1.53% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.00%
C43.DE was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about C43.DE.
In the previous month the buy percentage consensus was at a similar level.
C43.DE was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateJul 23, 2025
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 102.089M 56.88% | 92.78M -9.12% | 266.788M 187.55% | 218.51M -18.10% | 175.57M -19.65% | 142.8M -18.66% | 557.8M 290.62% | 753.02M 35.00% | 619.84M -17.69% | 498.68M -19.55% | 422.57M -15.26% | |
| EBITDA YoY % growth | 41.913M 126.92% | 9.974M -76.20% | 161.167M 1,515.87% | 108.5M -32.68% | 67.739M -37.57% | 100.98M 49.07% | 423.57M 319.46% | 573.78M 35.46% | 444.6M -22.51% | 339.46M -23.65% | 270.37M -20.35% | |
| EBIT YoY % growth | 28.057M 152.74% | -1.875M -106.68% | 148.882M 8,040.37% | 133.22M -10.52% | 43.649M -67.24% | 55.08M 26.19% | 381.56M 592.74% | 557.76M 46.18% | 428.58M -23.16% | 322.44M -24.77% | 253.34M -21.43% | |
| Operating Margin | 27.48% | -2.02% | 55.81% | 60.97% | 24.86% | 38.57% | 68.40% | 74.07% | 69.14% | 64.66% | 59.95% | |
| EPS YoY % growth | 1.05 29.36% | N/A 322.00% | N/A 78.51% | 6.03 -23.67% | 2.07 -65.73% | 2.99 44.57% | 19.21 542.74% | 28.25 47.06% | 21.93 -22.37% | 17.56 -19.91% | 15.17 -13.63% |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-27.68%
EPS Next 5 Year
29.02%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-19.24%
Revenue Next 5 Year
22.67%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-14.79%
EBIT Next 5 Year
28.59%
COSMO PHARMACEUTICALS NV / C43.DE Forecast FAQ
What is the price target for C43 stock?
10 analysts have analysed C43.DE and the average price target is 104.72 EUR. This implies a price increase of 114.58% is expected in the next year compared to the current price of 48.8.
What is the next earnings date for C43 stock?
COSMO PHARMACEUTICALS NV (C43.DE) will report earnings on 2025-07-23.
Can you provide the expected long term growth rate for COSMO PHARMACEUTICALS NV stock?
The expected long term growth rate for COSMO PHARMACEUTICALS NV (C43.DE) is -19.24%.